rmanj treatment paradigm


This week we had a chance to catch up with Dr. Jason M. Franasiak for some quick Q&A. Dr. Franasiak is a board certified Obstetrician Gynecologist, board certified Technical Supervisor in Embryology and Andrology, and lead physician of RMA’s South Jersey – Marlton Office. We wanted to know what his thoughts are on RMANJ’s treatment paradigm and how RMANJ is able to achieve success rates that are above the national average.

What makes RMANJ treatment different?

At Reproductive Medicine Associates of New Jersey, we work very hard to achieve good outcomes for our patients. With an *72.4% delivery rate in women under 35 (published by SART) per patient, RMANJ’s in vitro fertilization (IVF) success rates are unparalleled in the United States. When evaluating a fertility clinic, the best measure of success is that center’s delivery or live birth rates — as pregnancy rates don’t always tell the complete story. Although our delivery rates have been consistently above the national average for over a decade, the physicians and nurses understand that the treatment of infertility is more than just a published number and more than just IVF – it is about building healthy families.

How is RMANJ able to achieve such high SART success rates?

The ability to maintain high delivery rates at RMANJ is rooted in our experienced healthcare providers, individualized protocols, state-of-the-art laboratory conditions and modern techniques. Our healthcare team of physicians, nurses, embryologists, andrologists, acupuncturist, and counselors work at the forefront of their respective fields and are involved in cutting edge clinical care and research.

Many of the techniques which set us apart are in the reproductive science laboratory. Use of technology and procedures such as routine extended embryo culture, incorporating genetic testing of the embryos in the form of comprehensive chromosome screening (Select CCS), and paying careful attention to embryo and endometrial synchrony with use of frozen embryo transfer when appropriate maximizes potential.

It isn’t just about a delivery, but a healthy delivery. This means that transferring as few embryos as possible while still maintaining good success rates is paramount. RMANJ clinicians employ the technologies above to ensure they can transfer one embryo at a time in most circumstances in order to maximize the chance of a singleton, healthy delivery.

*SART 2014; Final live birth per patient for women under 35 include all non-banking autologous cycles and banking cycles with a thaw within 12 months of banking, representing outcomes for patients who were new to a given clinic in 2014, with births realized in 2014 and 2015.

For more information or to learn more about our Science, Success, and Support visit our Proven Fertility Treatments page or call 973-656-2089.

Dr. Jason M. Franasiak


Lead Physician, Reproductive Medicine Associates of New Jersey Marlton, NJ

View more blogs by Dr. Franasiak or follow him on Facebook & Twitter